Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

2 terminated out of 4 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

4Total
P 1 (1)
P 2 (3)

Trial Status

Terminated2
Recruiting1
Suspended1

Clinical Trials (4)

Showing 4 of 4 trials
NCT04902040Phase 1TerminatedPrimary

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

NCT05969860Phase 2Recruiting

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

NCT03375307Phase 2SuspendedPrimary

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

NCT05248789Phase 2TerminatedPrimary

OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer

Showing all 4 trials

Research Network

Activity Timeline